scholarly article | Q13442814 |
P2093 | author name string | Dino Amadori | |
P2860 | cites work | Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy | Q24240568 |
Cardioprotective interventions for cancer patients receiving anthracyclines | Q24243021 | ||
Different anthracycline derivates for reducing cardiotoxicity in cancer patients | Q24244087 | ||
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma | Q28297805 | ||
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer | Q28324350 | ||
Risk factors for doxorubicin-induced congestive heart failure | Q28328220 | ||
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials | Q34199968 | ||
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity | Q34239108 | ||
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group | Q34566901 | ||
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). | Q34742742 | ||
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma | Q40318856 | ||
Anthracyclines in the treatment of cancer. An overview | Q41637134 | ||
Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen | Q42248014 | ||
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion | Q42263291 | ||
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial | Q43223088 | ||
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. | Q44776010 | ||
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. | Q44796944 | ||
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia | Q46546765 | ||
Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma | Q46645702 | ||
Clinical evaluation of adriamycin, a new antitumour antibiotic | Q49203313 | ||
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127) | Q71579286 | ||
Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines | Q80678386 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 3s | |
P304 | page(s) | e1 | |
P577 | publication date | 2011-10-01 | |
P1433 | published in | Hematology reports | Q26841985 |
P1476 | title | Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma | |
P478 | volume | 3 |
Q30455450 | Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris. | cites work | P2860 |
Search more.